Halo is developing first-in-class, disease-modifying therapies using innovative approaches to edit the extracellular matrix
Halo is exploiting novel insights in ECM biology by selectively editing its components to address diseases with high unmet need that are driven by inflammation and fibrosis
We are building a differentiated pipeline based on novel insights into how dysregulation of the ECM drives disease.
Alterations to the ECM have strong associations with a variety of conditions including pulmonary hypertension, lung fibrosis, liver fibrosis, and diabetes.
Copyright © 2022 Halo Biosciences - All Rights Reserved.